Johan Lundkvist - AlzeCure Pharma Director Disease Biology
| ALZCUR Stock | SEK 1.80 0.09 4.76% |
Director
Mr. Johan Lundkvist serves as Director Disease Biology at AlzeCure Pharma AB. Johan Lundkvist has an academic career in neurobiology and dementia with a focus on Alzheimers disease and gammasecretase biology. Johan was appointed associate Professor at Karolinska Institutet in 2005. He has 14 years of experience of drug discovery, including from AstraZeneca team leader, project leader, member of the strategy team for neurology and responsible for project inlicensing to the neurology portfolio from academia. He holds Ph.D. Neurochemistry and Neurotoxicology at Stockholm University, Sweden. He is one of the Founders of the Company.
| Professional Marks | Ph.D |
| Phone | 46 8 52 80 03 99 |
| Web | https://www.alzecurepharma.se |
AlzeCure Pharma Management Efficiency
The company has return on total asset (ROA) of (0.7846) % which means that it has lost $0.7846 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.5536) %, meaning that it generated substantial loss on money invested by shareholders. AlzeCure Pharma's management efficiency ratios could be used to measure how well AlzeCure Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Olof Tyden | Oncopeptides AB | 70 | |
| Simon Cartmell | Bonesupport Holding AB | N/A | |
| Jarl Jungnelius | Oncopeptides AB | 66 | |
| Martin Jonsson | Camurus AB | 58 | |
| Mats Blom | Hansa Biopharma AB | 53 | |
| Per Sandberg | Camurus AB | 52 | |
| Marianne Alexandersson | Camurus AB | 60 | |
| Bjorn Odlander | Bonesupport Holding AB | 58 | |
| Per Samuelsson | Oncopeptides AB | 56 | |
| Anders Pedersen | Hansa Biopharma AB | 66 | |
| Lars Lidgren | Bonesupport Holding AB | 70 | |
| Kerstin Strinnholm | Camurus AB | 59 | |
| Eva Nilsagard | Hansa Biopharma AB | 54 | |
| Cecilia Wennborg | Oncopeptides AB | 55 | |
| Jennifer Jackson | Oncopeptides AB | N/A | |
| Bjorn Olsson | Camurus AB | 70 | |
| Lennart Johansson | Bonesupport Holding AB | 63 | |
| Jonas Brambeck | Oncopeptides AB | 59 | |
| Birgit Norinder | Hansa Biopharma AB | 69 | |
| Svein Mathisen | Camurus AB | 61 | |
| Bjrn Odlander | Bonesupport Holding AB | 58 | |
Management Performance
| Return On Equity | -1.55 | |||
| Return On Asset | -0.78 |
AlzeCure Pharma Leadership Team
Elected by the shareholders, the AlzeCure Pharma's board of directors comprises two types of representatives: AlzeCure Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AlzeCure. The board's role is to monitor AlzeCure Pharma's management team and ensure that shareholders' interests are well served. AlzeCure Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AlzeCure Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marta MD, Chief Officer | ||
| Johan Sandin, Chief Officer | ||
| Thomas Pollare, Chairman of the Board | ||
| Birgitta Lundvik, Chief Officer | ||
| Johan Lundkvist, Director Disease Biology | ||
| Gunnar Nordvall, Director Medicinal Chemistry | ||
| Magnus Halldin, Director DMPK | ||
| Martin Jnsson, Chief Officer | ||
| Ragnar Linder, Independent Director | ||
| Pirkko Tamsen, Independent Director | ||
| Mikael Widell, Head of Communications and Investor Relations | ||
| Ellen Donnelly, Independent Director | ||
| Pontus Forsell, Director Pharmacology | ||
| Matthias Rother, Medical Director | ||
| Annigje EsJohansson, Director |
AlzeCure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AlzeCure Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.55 | |||
| Return On Asset | -0.78 | |||
| Current Valuation | 173.51 M | |||
| Shares Outstanding | 59.19 M | |||
| Shares Owned By Insiders | 41.31 % | |||
| Shares Owned By Institutions | 6.48 % | |||
| Price To Book | 6.62 X | |||
| EBITDA | (77.2 M) | |||
| Net Income | (77.78 M) | |||
| Cash And Equivalents | 222.05 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards AlzeCure Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, AlzeCure Pharma's short interest history, or implied volatility extrapolated from AlzeCure Pharma options trading.
Pair Trading with AlzeCure Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AlzeCure Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AlzeCure Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against AlzeCure Stock
| 0.7 | LOGI-A | Logistea A Earnings Call Today | PairCorr |
| 0.69 | IPCO | International Petroleum Earnings Call This Week | PairCorr |
| 0.63 | LOGI-B | Logistea AB Series Earnings Call Today | PairCorr |
| 0.58 | SPRINT | Sprint Bioscience Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to AlzeCure Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AlzeCure Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AlzeCure Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AlzeCure Pharma to buy it.
The correlation of AlzeCure Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AlzeCure Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AlzeCure Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AlzeCure Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AlzeCure Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for AlzeCure Stock analysis
When running AlzeCure Pharma's price analysis, check to measure AlzeCure Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AlzeCure Pharma is operating at the current time. Most of AlzeCure Pharma's value examination focuses on studying past and present price action to predict the probability of AlzeCure Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AlzeCure Pharma's price. Additionally, you may evaluate how the addition of AlzeCure Pharma to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |